H.C. Wainwright reiterated a Buy rating and $8.00 price target on Traws Pharma (NASDAQ:TRAW), implying significant upside from the current price of $1.59. The biotech firm has a market cap of $24.09 million.
The company reported Q1 2026 results and secured financing to advance tivoxavir marboxil, its lead influenza antiviral, into a human challenge study. A private investment in public equity (PIPE) in April provided $10 million upfront and up to $60 million through milestone payments and warrants.
Management expects the funding to sustain operations into Q1 2027 and complete the planned human challenge trial. According to Bond.az analysis, Traws holds more cash than debt, though short-term obligations exceed liquid assets.
H.C. Wainwright views the financing as a key step to alleviate near-term cash concerns weighing on the stock. The firm maintains its bullish stance, highlighting tivoxavir marboxil's potential as a monthly influenza prophylaxis and ratutrelvir as a ritonavir-free COVID antiviral.
